The chemotherapy drug eribulin mesylate has received approval for treating liposarcoma that is unresectable or has metastasized (http://1.usa.gov/1ZWmPRo). Marketed as Halaven, the drug is approved for patients previously treated with chemotherapy that contained an anthracycline drug.
“Halaven is the first drug approved for patients with liposarcoma that has demonstrated an improvement in survival time,” Richard Pazdur, MD, of the FDA’s Center for Drug Evaluation and Research, said in a statement.
Voelker R. New Treatment for Liposarcoma. JAMA. 2016;315(9):861. doi:10.1001/jama.2016.1289